All Categories
How Marc Benioff paired experts in AI and prostate...
The company was formed in September 2021 and two years later lined up $90 million.
Artera Product Webinar – August 2025
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk pat [...]
Across the Prostate Cancer Continuum: Translating ArteraAI’s Biopsy Model...
Since launching the ArteraAI Prostate Test, Artera has used multimodal artificial intelligence (MMAI) algorithms to help thou [...]
FDA just signed off on AI predicting long-term cancer...
The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effecti [...]
FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool
The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artific [...]
Identifying Patients Who Will Benefit From Intensified Prostate Cancer...
Identifying men with high-risk, non-metastatic prostate cancer who will truly benefit from intensified treatment from therape [...]
U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced to [...]
AI Tool Accurately Predicts Prostate Cancer Outcomes Across Racial...
Mack Roach III, MD, professor of radiation oncology, medical oncology, and urology at the University of California, San Franc [...]